63 predicted drugs from Gordon et al. 	Drugs known to interact with proteins that interact with COVID-19 proteins based on mass-spec	chloroquine	compound 2	ruxolitinib	ribavirin	dabrafenib	pd-144418	4e2rcat	h-89	sapanisertib	az8838	ternatin 4	jq1	pb28	ac-55541	rvx-208	zinc95559591	linezolid	lisinopril	migalastat	indomethacin	fk-506	cct 365623	daunorubicin	chloram-phenicol	cpi-0610	gb110	xl413	rs-ppcc	zinc4326719	apicidin	ps3061	entacapone	camostat	dbet6	pevonedistat	midostaurin	tigecycline	compound 10	s-verapamil	silmitasertib	sanglifehrin a	captopril	abbv-744	az3451	mycophenolic acid	nafamostat	tmcb	haloperidol	zinc1775962367	wdb002	zotatifin	ihvr-19029	zinc4511851	mz1	bafilomycin a1	ponatinib	e-52862	verdinexor	tomivosertib	merimepodib	valproic acid	rapamycin	metformin
71 computationally predicted drugs from Farag et al. 	Computational screen for drugs that potentially bind to COVID-19 virus main protease enzyme (Mpro) substrate-binding pocket.	saquinavir	darunavir	mitoxantrone	variconazole	carbetocin	mefloquine	chloroquine	defroxamine	metamizole	etoposide	meloxicam	fosinopril	bepotastine	nelfinavir	furosemide	donedarone	timolol	metipanolol	omapatrilate	famciclovir	leflunomide	benzonatate	loratadine	teniposide	oxamniquine	simvastatin	delviradine	clofarabine	betamethasone	daunorubicin	candoxatril	zoledronic acid	moexpril	labetolol	indinavir	almitrine	iloperidone	indapamide	bricodar	cladribine	lansoprazole	levocabastine	methantheline	dipiverfin	flecainide	bexarotene	nafareline	imodium	dobutamine	ticonazole	pimozide	paricalcitol	indometacin	atovaqoune	fluvastatine	desoximetasone	losartan	cilizapril	abacavir	epoprostenol	repaglinide	vincristine	ziprosidone	cidofovir	sapropterin	mebendazol	diatrizoate	adefovir	deslanoside	rosuvastatin	tipranvir
21 computationally predicted drugs from Wang, Junmei	Hierarchical virtual screening (HVS) for drugs that target the newly resolved crystal structure of COVID-19  protease.	rutin	atosiban	hyaluronic acid	pentagastrin	saquinavir	macimorelin	flavin mononucleotide	darunavir	lopinavir	mitoxantrone	atazanavir	glutathione disulfide	3-{[(5r,6r)-5-benzyl-6-hydroxy-2,4-bis(4-hydroxybenzyl)-3-oxo-1,2,4-triazepan-1-yl]sulfonyl}benzonitril	fosaprepitant	cefonicid	cobicistat	carbetocin	hydroxyethyl cellulose	cangrelor	cid10011418	cid6102717
8 computationally predicted drugs from Contini, Alessandro	Virtual screening of drugs that may interact with the Covid-19 main protease	cobicistat	montelukast	travoprost	salvianolic acid b	indinavir	tyloxapol	octenidine	monomethyl auristatin e
11 computationally predicted drugs from Contini, Alessandro	Virtual screening of drugs that may interact with the 3CL-PRO proteinase	lopinavir	ritonavir	atazanavir	cobicistat	montelukast	salvianolic acid b	indinavir	tyloxapol	penfluridol	salmeterol	elbasvir
7 drugs predicted by the Ma'ayan Lab based on LINCS L1000 data	These drugs target the same space on the L1000FWD map and also have evidence from other sources 	chlorpromazine	loperamide	rs-504393	amlodipine	trifluoperazine	berbamine	terfenadine
10 computationally predicted drugs from Kumar & Singh	Candidates predicted from molecular docking simulations against main protease of SARS-cov2.	α-ketoamide 13b	raltegravir	nelfinavir	baloxavir-marboxil	tipranavir	dolutegravir	letermovir	lopinavir-ritonavir	maraviroc	tenofovir-disoproxil
16 potential anti-HCoV repurposable drugs	Based on comprehensive evaluation, the authors prioritized 16 candidate repurposable drugs for targeting 2019-nCoV/SARS-CoV-2. 	colchicine	equilin	eplerenone	melatonin	mercaptopurine	oxymetholone	camphor	sirolimus	dactinomycin	carvedilol	toremifene	paroxetine	quinacrine	mesalazine	irbesartan	emodin
7 molecular docking hits that may inhibit the COVID-19 main protease	Molecular docking showed several drug hits that interact with and inhibit the COVID-19 main protease	darunavir	metamizole	rosuvastatin	aliskiren	rolitetracycline	mopidamol	dipyridamole
Candidate Drugs from Homology Modeling of TMPRSS2	Homology Modeling of TMPRSS2 Yields Candidate Drugs That May Inhibit Entry of SARS-CoV-2 into Human Cells	nafamostat	otamixaban	darexaban	edoxaban	argatroban	letaxaban
Drug Gene Budger drugs that up regulate ACE2 based on L1000 	ACE2 is the co-receptor for COVID-19	apicidin	5-iodotubercidin	panobinostat	brd-k32896438	brd-k79222491	brd-k14704318	brd-a09984573	dorsomorphin	jak3-inhibitor-vi	arachidonyl-trifluoro-methane	manumycin-a	methylene-blue	pf-562271	cgp-60474	narciclasine	jnj-7706621	brd-k67484673	thm-i-94	emf-sumo1-11	jnk-9l	broad-sai-370	scriptaid	brd-k51556300	vorinostat	kinetin-riboside	tubastatin-a	trichostatin-a	er-27319	alvocidib	km-00927
Drug Gene Budger drugs that down regulate ACE2 based on L1000 	ACE2 is the co-receptor for COVID-19	mitoxantrone	etoposide	curcumin	brd-k79222491	cgp-60474	jnk-9l	brd-k71726959	cgs-15943	entinostat	fludarabine	pha-793887	torin-2	alvespimycin	phorbol-myristate-acetate	mocetinostat	mst-312	pyrvinium-pamoate	chembl-399379	radicicol	a-443644	zstk-474	tacedinaline	staurosporine	brefeldin-a	withaferin-a	erismodegib	ko-143	sa-792728	pirarubicin	importazole	lovastatin	cephaeline	brd-k68548958	pu-h71	alda-1	h-9	wortmannin	7b-cis	imatinib	sn-38	wz-3105	tgx-115	geldanamycin	tanespimycin
Drug Gene Budger drugs that up regulate ACE2 based on CREEDS 	ACE2 is the co-receptor for COVID-19	ribavirin	diclofenac	resveratrol	estradiol	imatinib	interferon beta-1b	neocarzinostatin	cytarabine	dasatinib	actinomycin d	lmp-420	sapphyrin pci-2050	interferon gamma-1b	apratoxin a	vemurafenib	cadmium	cisplatin	adenosine triphosphate	tretinoin	argyrin a	vanadium pentoxide	cediranib	pd173074	aminolevulinic acid	doxorubicin	nilotinib	natural alpha interferon	cetuximab
Drug Gene Budger drugs that down regulate ACE2 based on CREEDS 	ACE2 is the co-receptor for COVID-19	bexarotene	curcumin	quercetin	estradiol	apratoxin a	doxorubicin	vx	interferon beta-1a	clinafloxacin	lapatinib	4-hydroxynonenal	laccaic acid	fgfr-specific pd173074 inhibitor	etanercept	gefitinib	4-hydroxytamoxifen	mercury	hypochlorous acid	celecoxib	bisphenol a	antimony	aplidin	chromium
A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19	Computational methods combined with experimental validation to identify drug candidates for COVID-19	cvl218
Computational drug repurposing for COVID-19 with scRNA-seq an L1000 	Computational drug repurposing for COVID-19 with scRNA-seq an L1000 	benzyl-quinazolin-4-yl-amine	didanosine	ro-90-7501	camptothecin
Predicted drugs using structural biology methods from Beck et al	Predicted already known anti-viral drugs using structural biology methods from Beck et al 	darunavir	lopinavir	ritonavir	atazanavir	remdesivir	dolutegravir	kaletra	efavirenz
Virtual screening against 3C-like protease (3CL pro) structure	Virtual screening against 3C-like protease (3CL pro) structure	etoposide	teniposide	irinotecan	hesperidin	bolazine	ledipasvir	r428	uk-432097	lumacaftor	venetoclax	ditercalinium	dihydroergocristine	mk-3207	eluxadoline	velpatasvir
36 computationally predicted drugs against Covid-19 from Cava et al., 2020 (drugs that target ACE2 correlate genes)	Drugs that target the genes co-expressed with Angiotensin converting enzyme 2 (ACE2), the main cell receptor of SARS-CoV and SARS-CoV-2, according to Matador and DGIdb databases.	ivacaftor	naproxen	letrozole	retinol	didanosine	flutamide	nimesulide	lumacaftor	venetoclax	vatiquinone	alglucosidase alfa	tezacaftor	fluticasone propionate	trichostatin	lmb-2	photofrin	lentinan	vk-19911	amiodarone hydrochloride	mefenamic acid	l-778123	ibutilide fumarate	ns-398	fumarate	semapimod	mesalamine	iratumimab	cerulenin	thiabendazole	medroxyprogesterone acetate	qbw251	apigenin	dihydrokainate	lomustine	esflurbiprofen	sgn-30
Computational repurposing of approved drugs by transcriptomics and cheminformatics by Duarte et al.	Computational repurposing of approved drugs by transcriptomics and cheminformatics	trifluoperazine	metformin	raloxifene	fluoxetine	sunitinib	flupentixol	atorvastatin	butoconazole	reserpine
Drugs that alter gene expression of  genes whose expression is altered by  MHV infection	See the following paper.  Novel Method for Detection of Genes With Altered Expression Caused by Coronavirus Infection and Screening of Candidate Drugs for SARS-CoV-2  dx.doi.org/10.20944/preprints202004.0431.v1	primaquine	doxycycline	meloxicam	cortisone	quercetin	cytarabine	fenretinide	neomycin	pioglitazone	ascorbic acid	isotretinoin	pyrogallol	motexafin gadolinium	decitabine	troglitazone	tibolone
Drugs that alter gene expression of  genes whose expression is altered by  SARS-COV-2 infection	See the following paper.  A New Advanced In Silico Drug Discovery Method for Novel Coronavirus (SARS-CoV-2) with Tensor Decomposition-Based Unsupervised Feature Extraction  dx.doi.org/10.20944/preprints202004.0524.v1	mitoxantrone	doxycycline	meloxicam	fluticasone	quercetin	cgp-60474	alvocidib	radicicol	geldanamycin	gentamicin	sorafenib	atorvastatin	pioglitazone	ascorbic acid	isotretinoin	motexafin gadolinium	tibolone	ql-x-138	dibromochloromethane	canertinib	a-443654	c646	bx-795	trovafloxacin	chelerythrine chlorid	ql-xii-47
250 compounds predicted by Causaly AI using network analysis	Causaly AI releases Top 250 compounds for further research following CORD-19 Network Analysis	siltuximab	rutin	azithromycin	darunavir	lopinavir	ritonavir	amodiaquine	mycophenolate mofetil	sarilumab	colchicine	remdesivir	hydroxychloroquine	doxycycline	chloroquine	methylprednisolone	ruxolitinib	ribavirin	nelfinavir	cyclosporine	chlorpromazine	loperamide	niclosamide	simvastatin	indomethacin	fk-506	digoxin	ciclesonide	favipiravir	captopril	tetrandrine	mycophenolic acid	nafamostat	losartan	valproic acid	metformin	rosuvastatin	melatonin	mercaptopurine	sirolimus	dactinomycin	toremifene	emodin	pirfenidone	nystatin	hydrocortisone	astaxanthin	lycopene	thalidomide	naproxen	disulfiram	resveratrol	tamoxifen	omeprazole	capsaicin	methotrexate	acetazolamide	levofloxacin	nitazoxanide	ibuprofen	berberine	curcumin	ceftriaxone	ammonium chloride	itraconazole	nitric oxide	quercetin	oseltamivir	aliskiren	baricitinib	clarithromycin	dexamethasone	moxifloxacin	telmisartan	spironolactone	acetylcysteine	valsartan	cannabidiol	rivaroxaban	heparin	vorinostat	lovastatin	imatinib	interferon beta-1b	dasatinib	cisplatin	tretinoin	doxorubicin	cetuximab	interferon beta-1a	lapatinib	etanercept	gefitinib	celecoxib	methylene blue	bortezomib	alprostadil	arbidol	clomipramine	terconazole	tacrolimus	everolimus	propranolol	tofacitinib	glutathione	minocycline	riboflavin	paclitaxel	budesonide	amiodarone	lenalidomide	hesperidin	cholecalciferol	piclidenoson	biotin	luteolin	apigenin	fluoxetine	thioguanine	posaconazole	sorafenib	formoterol	caffeine	sunitinib	aluminum hydroxide	atorvastatin	pioglitazone	ascorbic acid	andrographolide	dextromethorphan	recombinant interferon alfa	hypericin	flavopiridol	trichostatin a	glucosamine	aspirin	interleukin-11	hemin	sinomenine	vitamin a	erlotinib	clopidogrel	streptokinase	sildenafil citrate	deoxyglucose	binetrakin	voriconazole	rosiglitazone	candesartan	mizoribine	eculizumab	vitamin d	lithium	nafamostat mesilate	poly iclc	baicalein	nim-811	anakinra	naringin	ursolic acid	acetovanillone	triptolide	amiloride	sitagliptin	ferulic acid	iota-carrageenan	nivolumab	sodium lactate	isoproterenol	alovudine	norepinephrine	ginger extract	rifampin	glycyrrhizic acid	polymyxin b	aprotinin	tocilizumab	mavrilimumab	sotrastaurin	il1rn protein, human	naringenin	thioctic acid	dimethyl fumarate	oxygen	glycopyrronium	bcg vaccine	piperacillin-tazobactam combination	interferon alfacon-1	fingolimod	ginseng preparation	recombinant 70-kd heat-shock protein	vitamin e	peoniflorin	propylthiouracil	licorice root extract	suramin	acetylglucosamine	rosmarinic acid	cordycepin	8-chloro-cyclic adenosine monophosphate	urinastatin	silybin	zinc	green tea extract	fumaric acid	rolipram	teicoplanin	sulforafan	genistein	silymarin	fucoidan	ursodiol	bevacizumab	fty-720	linoleic acid	coenzyme q10	recombinant interleukin-4	atn-161	recombinant interferon-gamma	camostate-mesilate	alpha 1-antitrypsin	eflornithine	calcitriol	das181	epigallocatechin gallate	saracatinib	afatinib	glyburide	omacetaxine	omacetaxine mepesuccinate	thymalfasin	exenatide	pterostilbene	cilostazol	pegylated interferon alfa	fenofibrate	nintedanib	eicosapentaenoic acid	liraglutide	ellagic acid	fasudil	fluorouracil	taurine	amoxicillin / clavulanate	escin	ethyl pyruvate	propolis	caffeic acid	interferon-beta	tranexamic acid	pentoxifylline
16 high-confidence repurposable drugs against human coronaviruses from Zhou et al. via network analysis	This set of 16 drugs high-confidence repurposable drugs against human coronaviruses is provided by Zhou et al. (2020) Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discovery, 6(1), pp.1-18.	colchicine	equilin	eplerenone	melatonin	mercaptopurine	oxymetholone	camphor	sirolimus	dactinomycin	carvedilol	toremifene	paroxetine	quinacrine	mesalazine	irbesartan	emodin
7 drugs inhibiting COVID-19 Mpro from Aly 2020 via molecular docking	This set of 6 drugs was shown to inhibit COVID-19 Mpro, and Darunavir is also included for reference. Aly (2020) Molecular docking reveals the potential of aliskiren, dipyridamole, mopidamol, rosuvastatin, rolitetracycline and metamizole to inhibit COVID-19 virus main protease. ChemRxiv.	darunavir	metamizole	rosuvastatin	aliskiren	rolitetracycline	mopidamol	dipyridamole
6 drugs inhibiting SARS-CoV-2 entry into cells from Rensi et al. via homology modeling of TMPRSS2	Homology modeling of TMPRSS2 was used to identify 6 drug candidates for COVID-19 (Rensi et al. (2020) Homology Modeling of TMPRSS2 Yields Candidate Drugs That May Inhibit Entry of SARS-CoV-2 into Human Cells. ChemRxiv.)	nafamostat	otamixaban	darexaban	edoxaban	argatroban	letaxaban
4 drugs for COVID-19 repurposing from Alakwaa via LINCS data	This study used the LINCS data to develop a pipeline for COVID-19 drug repurposing, and predicted these 4 drugs as top candidates. (Alakwaa (2020) Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data. Msystems, 5(2).)	benzyl-quinazolin-4-yl-amine	didanosine	ro-90-7501	camptothecin
8 drugs against SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) from Elfiky et al. via molecular docking	The SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) was targeted, and these 8 drugs were identified as top candidates. (Elfiky (2020) Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sciences, p.117592.)	galidesivir	remdesivir	ribavirin	tenofovir	setrobuvir	sofosbuvir	yak	guanosine derivative (idx-184)
5 Chymotrypsin-like protease (3CLpro) inhibitors of SARS-CoV-2 from Khan et al. via integrated computation	These 5 top candidate Chymotrypsin-like protease (3CLpro) inhibitors, relevant to viral replication and maturation, were identified via computational drug design (Khan et al. (2020) Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach. Journal of Biomolecular Structure and Dynamics, pp.1-13.).	saquinavir	darunavir	remdesivir	coumarine derivative	flavone derivative
4 drugs for targets 3CLpro & 2′-O-MTase from Khan et al. via computational analysis	Two top COVID-19 drug repurposing candidates were identified for each of two targets (3C-like proteinase (3CLpro) and 2′-O-ribose methyltransferase (2′-O-MTase)). (Khan et al. (2020) Targeting SARS-Cov-2: A systematic drug repurposing approach to identify promising inhibitors against 3C-like Proteinase and 2'-O-RiboseMethyltransferase. Journal of Biomolecular Structure and Dynamics, pp.1-40.)	raltegravir	dolutegravir	paritaprevir	bictegravir
11 potential covalent inhibitors of SARS-CoV-2 3CLpro from Liu et al. via SCAR strategy	These 11 covalent drugs target the main protease of SARS-CoV-2 (Liu et al. (2020) Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus. Bioinformatics.).	poziotinib	fostamatinib	cl-275838	leucal/folinic acid	itacitinib	vidupiprant	telcagepant	pilaralisib	itx5061	ziprasidone	oberadilol
3 drugs binding with SARS-CoV-2 protease against COVID-19 from Muralidharan et al. via docking & dynamics	Molecular docking and dynamics were used to assess these 3 drugs as COVID-19 repurposing candidates. (Muralidharan et al. (2020) Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 Protease against COVID-19. Journal of Biomolecular Structure and Dynamics, (just-accepted), pp.1-7.)	lopinavir	ritonavir	oseltamivir
61 COVID-19 drug repurposing candidates from Shah et al. via docking	Docking was used to identify these 61 COVID-19 drug repurposing candidates (Shah et al. (2020) In silico studies on therapeutic agents for COVID-19: Drug repurposing approach. Life Sciences, p.117652.).	galidesivir	darunavir	lopinavir	ritonavir	remdesivir	raltegravir	famciclovir	indinavir	favipiravir	maraviroc	adefovir	elbasvir	acyclovir	oseltamivir	danoprevir	baricitinib	tenofovir	amantadine	arbidol	sofosbuvir	didanosine	ganciclovir	entecavir	efavirenz	boceprevir	zanamivir	daclatasvir	delavirdine	zalcitabine	ravidasvir	cgp42112a	grazoprevir	sequinavir	dasabuvir	radalbuvir	brivudin	marboran/methisazone	dihydroxy propyladenine	faldaprevir	nsc306711 (ferristatin ii)	ombitasvir	stavudine	camostate	iodoxuridine	asunaprevir	vedroprevir	elvitegravir	nitrazoxanide	beclabuvir	foscarnet	vaniprevir	uprifosbuvir	telbivudine	telaprevir	amprenavir	nevirapine	simeprevir	velpatsvir	azidothimidine	mericitabine	abt450
Anton spike 2us molecular dynamics stability simulation	2 µs trajectories of FDA approved or investigational drug molecules that in simulation remained bound to a construct of the SARS-CoV-2 trimeric spike protein at positions that might conceivably allosterically disrupt the interaction between these proteins. The small molecule drugs and their initial binding poses were chosen from a combination of molecular dynamics simulation and docking performed using an FDA-investigational drug library. From the 5152 molecules we examined from the library, we found 50 that remained bound to the spike protein (none of the compounds discussed in these results is approved or known to be safe or effective to treat COVID-19).    The 50 putative spike protein binding small molecules locate at three regions on the spike trimer, a pocket in the RBD whose formation may possibly enhance RBD-RBD interactions in the closed conformation (8 molecules), a pocket between the two RBDs in the closed conformation (29 molecules), and a pocket that involves three RBDs in the closed conformation (13 molecules).    The simulations used the Amber ff99SB-ILDN force field5 for proteins, the CHARMM TIP3P model6 for water, and the generalized Amber force field for small molecules. The C- and N-peptide termini were capped with amide and acetyl groups respectively. The spike trimer construct was modeled from PDB entries 6VXX and 6VW1, only retaining the RBD and a short region from S1 fusion protein as a minimal system for maintaining a trimer assembly. The system was neutralized and salted with NaCl, with a final concentration of 0.15 M. The interval between frames is 1.2 ns. The simulations were conducted at 310 K in the NPT ensemble.	darunavir	ritonavir	atazanavir	captopril	nitazoxanide	naloxone	tenofovir	atropine	rivaroxaban	lapatinib	alprostadil	tadalafil	cefixime	zileuton	clobazam	efavirenz	fluticasone propionate	ketoconazole	atorvastatin	megestrol acetate	telaprevir	recoflavone	triazolam	divalproex sodium	pelitrexol	cobimetinib	raltitrexed	cp-195543	amcinonide	methsuximide	nilutamide	cefamandole nafate	iloprost	azilsartan	duloxetine	levomefolate calcium	deferasirox	brigatinib	rebamipide	nebivolol	treprostinil	azd-8330	isocarboxazid	lometrexol	aprepitant	vorapaxar	dihydroergotamine	calcifediol	terazosin	lomibuvir
Anton ACE2 2us molecular dynamics stability simulation	2 µs trajectories of FDA approved or investigational drug molecules that in simulation remained bound to the ectodomain of human ACE2 at positions that might conceivably allosterically disrupt the interaction between these proteins. The small molecule drugs and their initial binding poses were chosen from a combination of molecular dynamics simulation and docking performed using an FDA-investigational drug library. From the 5152 molecules we examined from the library, we found 78 that remained bound to ACE2 (none of the compounds discussed in these results is approved or known to be safe or effective to treat COVID-19).    The 78 putative ACE2 binding small molecules locate at three regions on ACE2: a pocket underneath a helical bundle (residue 20-100; 51 molecules), a pocket involving a beta-hairpin structure (residue 346 to 360; 14 molecules) and a pocket behind a loop (residue 131-142; 13 molecules). The helical bundle and the beta-hairpin structure are known to interact with the RBD (receptor binding domain) of the spike protein, and the loop structure is known to be involved in ACE2 homo-dimerization.    The simulations used the Amber ff99SB-ILDN force field for proteins, the CHARMM TIP3P model for water, and the generalized Amber force field for small molecules. The C- and N-peptide termini were capped with amide and acetyl groups respectively. The ectodomain of human ACE2 is from PDB entry 6VW1. The system was neutralized and salted with NaCl, with a final concentration of 0.15 M. The interval between frames is 1.2 ns. The simulations were conducted at 310 K in the NPT ensemble.	primaquine	mefloquine	chloroquine	methylprednisolone	elbasvir	midazolam	pimecrolimus	azathioprine	dabigatran	panobinostat	imatinib	dasatinib	fluvastatin	prazosin	doxazosin	metronidazole	gentamicin	kanamycin	acalabrutinib	fluoxetine	topiramate	pioglitazone	delavirdine	elvitegravir	nevirapine	brigatinib	tt-232	dimenhydrinate	ipamorelin	netilmicin	nafithromycin	copanlisib	deutivacaftor	e7107	kpt-9274	sivifene	ruzasvir	aclidinium	afeletecan	bromocriptine	ceritinib	berzosertib	tivozanib	cimicoxib	sonidegib	bekanamycin	methylnaltrexone	birinapant	bunazosin	propylhexedrine	eletriptan	brompheniramine	prochlorperazine	pramoxine	barusiban	desvenlafaxine	disopyramide	rabeprazole	orphenadrine	amentoflavone	dacomitinib	elamipretide	bendamustine	brequinar	capreomycin	netupitant	ziritaxestat	modithromycin	pelitinib	vadimezan	conivaptan	lixivaptan	perphenazine	ticlopidine	tobramycin	gemifloxacin
42 COVID-19 drug repurposing candidates targeting papain-like protease (PLpro) from Wu et al. via computational methods	Homology modeling of proteins encoded by SARS-CoV-2 genes and drug screening using the target papain-like protease (PLpro) were used to identify 42 COVID-19 drug repurposing candidates. Tables 1 & 2 of Wu et al. (2020) Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B.	doxycycline	ribavirin	tigecycline	chloramphenicol	dantrolene	sulfasalazine	aspartame	sildenafil	glutathione	riboflavin	valganciclovir	isotretinoin	rosmarinic acid	silybin	nicardipine	hesperetin	cefamandole	2,2-di(3-indolyl)-3-indolone	beta-thymidine	floxuridine	phaitanthrin d	pemetrexed	iopromide	(s)-(1s,2r,4as,5r,8as)-1-formamido-1,4a-dimethyl-6-methylene-5-((e)-2-(2-oxo-2,5-dihydrofuran-3-yl)ethenyl)decahydronaphthalen-2-yl-2-amino-3-phenylpropanoate	(–)-epigallocatechin gallate	chrysin	baicalin	sugetriol-3,9-diacetate	ademetionine	platycodin d	magnolol	l(+)-ascorbic acid	chlorphenesin carbamate	piceatannol	masoprocol	acetophenazine	2-(3,4-dihydroxyphenyl)-2-[[2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2h-1-benzopyran-3-yl]oxy]-3,4-dihydro-2h-1-benzopyran-3,4,5,7-tetrol	levodropropizine	reproterol	oxprenolol	2,2′-cyclocytidine	neohesperidin
53 COVID-19 drug repurposing candidates targeting 3-chymotrypsin-like protease (3CLpro) from Wu et al. via computational methods	Homology modeling of proteins encoded by SARS-CoV-2 genes and drug screening using the target 3-chymotrypsin-like protease (3CLpro) were used to identify 53 COVID-19 drug repurposing candidates. Tables 3 & 4 of Wu et al. (2020) Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B.	flavin mononucleotide	doxycycline	montelukast	candoxatril	almitrine	tigecycline	carvedilol	chlorhexidine	famotidine	telmisartan	hesperidin	lutein	oxytetracycline	pioglitazone	rosmarinic acid	amprenavir	conivaptan	nicardipine	2,2-di(3-indolyl)-3-indolone	(s)-(1s,2r,4as,5r,8as)-1-formamido-1,4a-dimethyl-6-methylene-5-((e)-2-(2-oxo-2,5-dihydrofuran-3-yl)ethenyl)decahydronaphthalen-2-yl-2-amino-3-phenylpropanoate	neohesperidin	phyllaemblinol	phenethicillin	betulonal	alfuzosin	demeclocycline	oleanolic acid	cefpiramide	lymecycline	andrographiside	deacetylcentapicrin	(1s,2r,4as,5r,8as)-1-formamido-1,4a-dimethyl-6-methylene-5-((e)-2-(2-oxo-2,5-dihydrofuran-3-yl)ethenyl)decahydronaphthalen-2-yl2-nitrobenzoate	theaflavin 3,3′-di-o-gallate	chrysin-7-o-beta-glucuronide	(1s,2r,4as,5r,8as)-1-formamido-1,4a-dimethyl-6-methylene-5-((e)-2-(2-oxo-2,5-dihydrofuran-3-yl)ethenyl)decahydronaphthalen-2-yl5-((r)-1,2-dithiolan-3-yl) pentanoate	stigmast-5-en-3-ol	andrograpanin	biorobin	gnidicin	cosmosiin	cleistocaltone a	estradiol valerate	berchemol	mimosine	2-((1r,5r,6r,8as)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethyl benzoate	isodecortinol	progabide	kouitchenside i	cilastatin	cerevisterol	carminic acid	nepafenac	2beta-hydroxy-3,4-seco-friedelolactone-27-oic acid
40 COVID-19 drug repurposing candidates targeting RNA-dependent RNA polymerase (RdRp) from Wu et al. via computational methods	Homology modeling of proteins encoded by SARS-CoV-2 genes and drug screening using the target RNA-dependent RNA polymerase (RdRp) were used to identify 40 COVID-19 drug repurposing candidates. Tables 5 & 6 of Wu et al. (2020) Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B.	atovaquone	cortisone	chlorhexidine	itraconazole	fludarabine	valganciclovir	tibolone	cefuroxime	silybin	bromocriptine	baicalin	sugetriol-3,9-diacetate	2-(3,4-dihydroxyphenyl)-2-[[2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2h-1-benzopyran-3-yl]oxy]-3,4-dihydro-2h-1-benzopyran-3,4,5,7-tetrol	betulonal	andrographiside	theaflavin 3,3′-di-o-gallate	gnidicin	2-((1r,5r,6r,8as)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethyl benzoate	2beta-hydroxy-3,4-seco-friedelolactone-27-oic acid	dabigatran etexilate	(r)-((1r,5as,6r,9as)-1,5a-dimethyl-7-methylene-3-oxo-6-((e)-2-(2-oxo-2,5-dihydrofuran-3-yl)ethenyl)decahydro-1h-benzo[c]azepin-1-yl)methyl2-amino-3-phenylpropanoate	2beta,30beta-dihydroxy-3,4-seco-friedelolactone-27-lactone	(1s,2r,4as,5r,8as)-1-formamido-1,4a-dimethyl-6-methylene-5-((e)-2-(2-oxo-2,5-dihydrofuran-3-yl)ethenyl)decahydronaphthalen-2-yl5-((r)-1,2-dithiolan-3-yl)pentanoate	pancuronium bromide	phyllaemblicin b	14-hydroxycyperotundone	cromolyn	idarubicin	novobiocin	1,2,6-trimethoxy-8-[(6-o-β-d-xylopyranosyl-beta-d-glucopyranosyl)oxy]-9h-xanthen-9-one	ceftibuten	8-(beta-d-glucopyranosyloxy)-1,3,5-trihydroxy-9h-xanthen-9-one	1,7-dihydroxy-3-methoxyxanthone	1,8-dihydroxy-6-methoxy-2-[(6-o-beta-d-xylopyranosyl-beta-d-glucopyranosyl)oxy]-9h-xanthen-9-one	14-deoxy-11,12-didehydroandrographolide	fenoterol	chenodeoxycholic acid	diphenoxylate	benzylpenicilloyl g	gniditrin
81 COVID-19 drug repurposing candidates from Gysi et al. via network medicine analysis	Network-based analysis of lung and other tissues was used to derive 81 COVID-19 drug repurposing candidates. Table 2 from Gysi et al. (2020) Network medicine framework for identifying drug repurposing opportunities for covid-19. arXiv preprint arXiv:2004.07229.	azithromycin	lopinavir	mitoxantrone	ritonavir	atovaquone	colchicine	cobicistat	hydroxychloroquine	chloroquine	ruxolitinib	ribavirin	montelukast	leflunomide	digoxin	ponatinib	metformin	melatonin	dactinomycin	mesalazine	levamisole	theophylline	ivermectin	thalidomide	omeprazole	methotrexate	quercetin	dexamethasone	aminolevulinic acid	doxorubicin	bortezomib	fluvastatin	propranolol	sildenafil	tadalafil	doxazosin	deferoxamine	flutamide	isoniazid	nitroglycerin	dapagliflozin	auranofin	verapamil	praziquantel	methimazole	atorvastatin	levothyroxine	ascorbic acid	rosiglitazone	sitagliptin	calcitriol	glyburide	cilostazol	nintedanib	allopurinol	rabeprazole	interferon-beta-1a	rifabutin	hydralazine	aminoglutethimide	pomalidomide	tenofivir	nitroprusside	sulfanilamide	sulfinpyrazone	carfilzomib	carbamazepine	fluconazole	romidepsin	mebendazole	cinacalcet	mexiletine	selegiline	folic acid	azelastine	troleandomycin	dimethylfumarate	pentamidine	griseofulvin	rifaximin	gemfibrozil	interferon-beta-1b
9 COVID-19 drug repurposing candidates from Kumar via PPI network analysis	Protein-protein interaction (PPI) network analysis was used to identify 9 candidate drugs for COVID-19 repurposing. Note that "statins" was included as a 10th candidate in this paper, but is excluded here due to lack of specificity of drug name. Kumar (2020) COVID-19: A drug repurposing and biomarker identification by using comprehensive gene-disease associations through protein-protein interaction network analysis. Preprints.org	chloroquine	rapamycin	penicillin	paclitaxel	lenalidomide	sorafenib	pentoxifylline	cortisol	thalidome
2 COVID-19 repurposing candidates from Glinsky via activators and repressors of ACE2 and FURIN	Human genes required for SARS-CoV-2 entry into human cells, ACE2 and FURIN, were employed as baits to build genomics-guided maps of up-stream regulatory elements, their expression and functions. Panels of repressors and activators were then employed to identify drug repurposing candidates. Glinsky (2020) Harnessing powers of genomics to build molecular maps of coronavirus targets in human cells: a guide for existing drug repurposing and experimental studies identifying candidate therapeutics to mitigate the pandemic COVID-19. ChemRxiv.	quercetin	vitamin d
6 COVID-19 drug repurposing candidates against SARS‐CoV-2 spike protein receptor binding domain (RBD) from Arun et al. via docking	In silico molecular modeling and docking were used to identify 6 drug candidates against the SARS‐CoV-2 spike protein receptor binding domain (RBD). Arun et al. (2020) Drug repurposing to identify therapeutics against COVID 19 with SARS-Cov-2 spike glycoprotein and main protease as targets: An in silico study. ChemRxiv	cidofovir	tenofovir	fludarabine	cytarabine	raltitrexed	lamivudine
6 COVID-19 drug repurposing candidates against active site of SARS-CoV-2 main proteases from Arun et al. via docking	In silico molecular modeling and docking were used to identify 6 drug candidates against the active site of SARS-CoV-2 main proteases. Arun et al. (2020) Drug repurposing to identify therapeutics against COVID 19 with SARS-Cov-2 spike glycoprotein and main protease as targets: an in silico study. ChemRxiv	valganciclovir	tafenoquine	petrichloral	ribostamycin	framycetin	vandetanib
2 COVID-19 drug repurposing candidates from Chakrabortya et al. via docking & protein-ligand interactions	Docking and protein-ligand interactions were used to identify 2 drugs that have stronger binding affinity than remdesivir. Chakrabortya et al. (2020) Drug Repurposing against SARS-CoV-2 RDRP-a computational quest against CoVID-19. Europe PMC.	n-alpha-[(benzyloxy)carbonyl]-n-[(1r)-4- hydroxy-1-methyl-2-oxobutyl]-l-phenylalaninamide	s-[5-(trifluoromethyl)-4h-1,2,4- triazol-3-yl] 5-(phenylethynyl) furan-2 -carbothioate
4 drugs against COVID-19 RNA-dependent RNA polymerase (RdRp) from Elfiky via Sequence Analysis, Modeling & Docking	Sequence analysis, modeling and docking were used to identify 4 potent drugs against COVID-19 RNA-dependent RNA polymerase (RdRp). Elfiky, A.A., 2020. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sciences, p.117477.	ribavirin	sofosbuvir	idx-184	remidisvir
19 drugs against COVID-19 main protease from Kandeel & Al-Nazawi via docking	Molecular modeling, virtual screening, docking, and other methods were used to identify 19 drugs against the COVID-19 main protease. Note that this paper states that 20 drugs are present in Table 2, but only 19 drugs are actually listed. Kandeel & Al-Nazawi (2020) Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. Life Sciences, p.117627.	ribavirin	nicotinamide	pyrazinamide	aminophylline	propylthiouracil	telbivudine	triflusal	methoxamine hydrochloride	zonisamide	cysteamine hcl	methazolamide	vitamin b12	bemegride	temozolomide	tioxolone	amiloride hydrochloride	aminosalicylate sodium	chromocarb	(+,-)-octopamine hcl
4 drug repurposing candidates for COVID-19 from Kim & Kim via enrichment & network analyses	Enrichment analysis and network analysis were performed on 4 drug candidates against COVID-19. IL6 and TNF were identified as potential targets. Synergistic combinations of these drugs were tested. Kim & Kim, M (2020) In silico synergistic drug repurposing for combating novel coronavirus (COVID-19) outbreaks. Europe PMC.	hydroxychloroquine	ribavirin	lisinopril	oseltamivir
6 candidate drugs against active site of COVID-19 Main Protease from Kumar et al. via virtual screening	The PyRX virtual screening tool was used to identify 6 drugs showing interactions with the active site of the COVID-19 Main Protease (Mpro). Kumar et al. (2020) In silico identification of potent FDA approved drugs against Coronavirus COVID-19 main protease: A drug repurposing approach. Chemical Biology Letters, 7(3), pp.166-175.	nelfinavir	rhein	withanolide d	withaferin a	aloe-emodin	enoxacin
4 drugs against COVID-19 3c-like Protease from Liu et al. via Consecutive Histogram Monte Carlo & Movable Type analyses	Consecutive Histogram Monte Carlo sampling method and Movable Type free energy method were used to identify 4 drug candidates against the COVID-19 3c-like protease. Liu et al. (2020) Computational Evaluation of the COVID-19 3c-like Protease Inhibition Mechanism, and Drug Repurposing Screening. ChemRxiv	saralasin	enalkiren	rupintrivir	trv-120027
4 drugs against ACE2, NSP12, and NSP16 facilitators of COVID-19 from Barik et al. via docking	Docking analysis was used to vet 4 FDA-approved drugs that are candidates against the COVID-19 facilitator proteins ACE2, NSP12, and NSP16. Barik et al. (2020) Molecular docking and binding mode analysis of selected FDA approved drugs against COVID-19 selected key protein targets: An effort towards drug repurposing to identify the combination therapy to combat COVID-19. arXiv preprint arXiv:2004.06447.	remdesivir	hydroxychloroquine	chloroquine	arbidol
8 potential inhibitor drugs against SARS-CoV-2 Mpro from Cavasotto & Di Filippo via docking	Docking was used to vet 8 candidate drugs against SARS-CoV-2 Mpro that are currently undergoing clinical trials. Table 1 from Cavasotto & Di Filippo (2020) In silico Drug Repurposing for COVID-19: Targeting SARS-CoV-2 Proteins through Docking and Quantum Mechanical Scoring. ChemRxiv	lopinavir	ritonavir	indinavir	angiotensinamide	felypressin	samatasvir	briladicin	cr665
7 potential inhibitor drugs against SARS-CoV-2 Papain-Like Proease (PLpro) from Cavasotto & Di Filippo via docking	Docking was used to vet 7 candidate drugs against SARS-CoV-2 Papain-Like Protease (PLpro) that are currently undergoing clinical trials. Table 2 from Cavasotto & Di Filippo (2020) In silico Drug Repurposing for COVID-19: Targeting SARS-CoV-2 Proteins through Docking and Quantum Mechanical Scoring. ChemRxiv.	pilaralisib	cilazapril	picotamide	pf-610355	indisulam	denibulin	tiracizine
8 inhibitors of SARS-CoV-2 Main Protease from Durdagi et al. via docking & molecular dynamics	Docking and molecular dynamics simulations were performed to identify 8 compounds as SARS-CoV-2 Main Protease inhibitors. Durdagi et al. (2020) Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike Receptor-Binding Domain Bound with ACE2 COVID19 Target Proteins: A Virtual Drug Repurposing Study. ChemRxiv	ritonavir	cefpiramide	rotigaptide	cefotiam	pinokalant	telinavir	pimelautide	terlakiren
5 inhibitors of SARS-CoV-2 ACE-2/Spike protein domain from Durdagi et al. via docking & molecular dynamics	Docking and molecular dynamics simulations were performed to identify 5 compounds as SARS-CoV-2 ACE-2/Spike protein domain inhibitors. Durdagi et al. (2020) Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike Receptor-Binding Domain Bound with ACE2 COVID19 Target Proteins: A Virtual Drug Repurposing Study. ChemRxiv	rotigaptide	denopamine	benzquercin	bometolol	naminterol
64 potential COVID-19 protease inhibitors from Kouznetsova et al. via data mining & docking	Data mining and docking were used to identify 64 compounds that are potential inhibitors of COVID-19 protease. Table 2 of Kouznetsova et al. (2020) Potential COVID-19 Protease Inhibitors: Repurposing FDA-approved Drugs. ChemRxiv	rutin	azithromycin	atosiban	pentagastrin	carbetocin	doxycycline	cangrelor	indinavir	tigecycline	rolitetracycline	streptomycin	betrixaban	icatibant	citicoline	gentamicin	bleomycin	hesperidin	tetracycline	eluxadoline	boceprevir	telaprevir	amprenavir	tobramycin	iopromide	demeclocycline	cefpiramide	lymecycline	carfilzomib	ribostamycin	framycetin	iopamidol	steviolbioside	bemotrizinol	goserelin	glecaprevir	viomycin	1,2-icosapentoyl-sn-glycero-3-phosphoserine	iomeprol	polymixin b	roxithromycin	elagolix	caspofungin	plazomicin	flavin adenine dinucleotide	ioxaglic acid	macitentan	omadacycline	iodixanol	etelcalcetide	micronomicin	octreotide	calcium glubionate	mithramycin	amikacin	valrubicin	ioversol	methacycline	cyclosporin a	neratinib	chlortetracycline	pantethine	eravacycline	sarecycline	ticagrelor
10 FDA-approved drugs for COVID-19 repurposing against SARS Coronavirus 3C-like Protease from Mohapatra et al. via machine learning & docking	A machine learning model based on the Naïve Bayes algorithm, as well as docking analysis, were used to predict 10 FDA-approved drugs for COVID-19 repurposing against the SARS Coronavirus 3C-like Protease. Table 1 from Mahapatra et al. (2020) Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking. medRxiv.	saquinavir	darunavir	lopinavir	ritonavir	atazanavir	tipranavir	indinavir	paritaprevir	amprenavir	fosamprenavir
4 drugs against SARS-CoV main protease from Li et al. via high-throughput screening	High-throughput screening was used to identify 4 small-molecule drugs against SARS-CoV main protease. Li et al. (2020) Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening. BioRxiv	nelfinavir	bictegravir	tegobuvir	prulifloxacin
10 inhibitors against SARS-CoV-2 Main Protease (Mpro) from Liu & Wang via docking	Modeling and docking analyses were used to identify 10 inhibitors against SARS-CoV-2 Main Protease (Mpro). Liu & Wang (2020) Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. Journal of Genetics and Genomics.	bepotastine	epoprostenol	epirubicin	icatibant	colistin	aprepitant	perphenazine	caspofungin	valrubicin	vapreotide
3 drugs against SARS-CoV-2 spike glycoprotein 6vsb from Ubani et al. via docking	Docking analysis was used to identify 3 drugs against SARS-CoV-2 spike glycoprotein 6vsb. Ubani et al. (2020) Molecular Docking Analysis Of Some Phytochemicals On Two SARS-CoV-2 Targets. bioRxiv.	solanidine	scopodulic acid	sylibinin
3 drugs against SARS-CoV-2 main protease Mpro 6lu7 from Ubani et al. via docking	Docking analysis was used to identify 3 drugs against SARS-CoV-2 main protease Mpro 6lu7. Ubani et al. (2020) Molecular Docking Analysis Of Some Phytochemicals On Two SARS-CoV-2 Targets. bioRxiv.	solanidine	sylibinin	dammarenolic acid
7 drugs for COVID-19 repurposing against SARS-CoV-2 protease enzyme from Parikesit & Nurdiansyah via docking	Docking analysis was used to evaluate 7 drugs for COVID-19 repurposing, against SARS-CoV-2 protease enzyme. Tables 1, 2 and 3 of Parikesit & Nurdiansyah (2020) Drug Repurposing Option for COVID-19 with Structural Bioinformatics of Chemical Interactions Approach. Cermin Dunia Kedokteran, 47 (3), pp.222-226.	lopinavir	remdesivir	ribavirin	oseltamivir	peramivir	zanamivir	chloroquine phosphate
19 drugs against spike protein (S-protein) of SARS-CoV-2 interacting with human ACE2 receptor from Smith via docking	Docking was used to identify 19 drugs against spike protein (S-protein) of SARS-CoV-2 interacting with the human ACE2 receptor. Table 3 from Smith (2020) Repurposing therapeutics for covid-19: Supercomputer-based docking to the sars-cov-2 viral spike protein and viral spike protein-human ace2 interface. ChemRxiv	sapropterin	quercitin	demethyl-coclaurine	quercetol	pemirolast	vildagliptin	vidarabine	benserazide	tazobactum	phenformin hcl	eriodictyol	nitrofurantoin	carbazochrome	luteolin-monoarabinoside	pyruvic acid calcium isoniazid	protirelin
11 drugs against 3 SARS-CoV-2 targets from Encinar & Menendez via docking	Docking was used to identify 11 drug candidates against 3 COVID-19-related targets: (1) S-adenosyl-l-methionine-binding pocket of nsp16, (2) the unique “activating surface” between nsp16 & nsp10, & (3) RNA-binding groove of nsp16. Encinar & Menendez (2020) Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA. Viruses, 12(5): E525	mk-3207	itacitinib	sonidegib	tegobuvir	antrafenine	phthalocyanine	siramesine	pf-04457845	tg-100801	bemcentinib	lifitegrast
6 drugs against SARS-CoV-2 Mpro from Mittal et al. via docking	Docking & molecular dynamics were used to identify 6 drugs against SARS-CoV-2 main protease (Mpro). Mittal et al. (2020) Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach. J Biomol Struct Dyn, May 2020, 1-26.	nelfinavir	birinapant	octreotide	lypression	leupeptin hemisulphate	pepstatin a
11 drugs against 3 SARS-CoV-2 targets from Hijikata et al. via homology modeling	Homology modeling was used to identify 11 drugs against 3 targets: 2'-O-Ribose methyl transferase (nsp16), 3C-like proteinase, and ACE. Hijikata et al. (2020) Knowledge-based structural models of SARS-CoV-2 proteins and their complexes with potential drugs. FEBS Letters, May 7 2020, doi: 10.1002/1873-3468.13806	sinefungin	7-methyl-guanosine-5'-triphosphate-5'-guanosine	s-adenosyl-l-methionine	1-((2s)-2-{[(1s)-1-carboxy-3-phenylpropyl]amino}propanpyl)-l-proline	[n2-[(s)-1-carboxy-3-phenylpropyl]-l-lysyl-l-proline	ac-estlq-h	c4z inhibitor	n-[(5-methylisoxazol-3-yl)carbonyl]alanyl-l-valyl-n~1-((1r,2z)-4-(benzyloxy)-4-oxo-1-{[(3r)-2-oxopyrrolidin-3-yl]methyl}but-2-enyl)-l-leucinamide	ace-ser-ala-val-alc-his-h	l-captopril	(5s,8s,14r)-ethyl11-(3-amino-3-oxopropyl)-8-benzyl-14-hydroxy-5-isobutyl-3,6,9,12-tetraoxo-1-phenyl-2-oxa-4,7,10,11-tetraazapentadecan-15-oate
7 drugs against SARS-CoV-2 Mpro from Al-Khafaji et al. via docking	Docking analysis was used to identify 7 drugs against the SARS-CoV-2 main protease (Mpro). Al-Khafaji K et al. (2020) Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2. J Biomol Struct Dyn. May 15, 2020: 1-9	saquinavir	ritonavir	remdesivir	oseltamivir	delavirdine	prevacid	cefuroxime axetil
8 drugs against SARS-CoV-2 RdRp from Elfiky via docking and molecular dynamics	Molecular modeling, docking, and dynamics simulations were used to identify 8 drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp). Elfiky AA (2020) SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: An in silico perspective. J Biomol Struct Dyn, May 6, 2020; pp. 1-9	galidesivir	remdesivir	hydroxychloroquine	ribavirin	favipiravir	tenofovir	sofosbuvir	cefuroxime
10 drugs against SARS-CoV-2 Mpro from Odhar et al. via docking & molecular dynamics	Docking & molecular dynamics analyses were used to identify 10 drugs against SARS-CoV-2 main protease (Mpro). Table 2 from Odhar HA et al. (2020) Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus. Bioinformation, March 31, 2020: 16(3): 236-244	ponatinib	tolvaptan	sonidegib	conivaptan	azelastine	idelalisib	loxapine	olaparib	perampanel	suvorexant
8 drugs against SARS-CoV-2 Mpro & TMPRSS2 from Elmezayen et al. via docking	Docking, homology modeling, molecular dynamics, and free energy analyses were used to identify 8 drugs against two SARS-CoV-2 targets: main protease (Mpro) and TMPRSS2. Elmezayen AD et al. (2020) Drug repurposing for coronavirus (COVID-19): In silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes. J Biomol Struct Dyn, April 26, 2020: 1-13	loprazolam	zinc000000702323	rubitecan	zinc000015988935	zinc000103558522	talampicillin	zinc000012481889	lurasidone
4 drugs against SARS-CoV-2 Mpro from Pant et al. via docking	Docking, binding energy, and molecular dynamics analyses were used to identify 4 drugs against SARS-CoV-2 main protease (Mpro). Pant S et al. (2020) Peptide-like and small-molecule inhibitors against Covid-19. J Biomol Struct Dyn, May 6, 2020; 1-10	darunavir	lopinavir	ritonavir	cobicistat
4 drugs against SARS-CoV-2 spike protein & ACE2 from Wahedi et al. via docking	Docking, molecular dynamics, and free energy were used to identify 4 drugs against SARS-CoV-2 spike protein & human ACE2 receptor complex. Table 2 from Wahedi HM et al. (2020) Stilbene-based natural compounds as promising drug candidates against COVID-19. J Biomol Struct Dyn, 5/012/2020, pp. 1-10	resveratrol	pterostilbene	piceatannol	pinosylvin
15 drugs against SARS-CoV-2 Mpro, RdRp & hACE-2 from Joshi et al. via docking & molecular dynamics	Docking & molecular dynamics were used to identify 15 drugs against SARS-CoV-2 main protease (Mpro), RNA-dependent RNA polymerase (RdRp), and human angiotensin-converting enzyme 2 (hACE-2). From Table 1 of Joshi et al. (2020) Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease. J Biomol Struct Dyn, 5/05/2020, 1-16.	saquinavir	hesperidin	baicalin	biorobin	phyllaemblicin b	myricitrin	cassameridin	afzelin	taiwanhomoflavone a	delta-viniferin	-(-)asperlicin	chrysanthemin	lactucopicrin 15-oxalate	nympholide-a	scalarane
13 molecules from Chinese herbal medicine against PLpro, 3CLpro & spike proteins from Zhang et al. via docking	Docking was used to identify 13 molecules from Chinese herbal medicine against SARS-CoV-2 papain-like protease (PLpro), 3C-like protease (3CLpro), and spike proteins. From Table 1 of Zhang et al. (2020) In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus. Journal of integrative medicine, 18(2), pp.152-158.	kaempferol	quercetin	betulinic acid	lignan	moupinamide	tanshinone iia	n-cis-feruloyltyramine	desmethoxyreserpine	sugiol	coumaroyltyramine	dihydrotanshinone i	cryptotanshinone	dihomo-gamma-linolenic acid
7 drugs against 3CLpro, PLpro, RdRp & Spike Protein from Yu et al. via docking	Docking analysis was used to identify 7 drugs against 4 targets: SARS-CoV-2 main protease (3CL protease), papain-like protease (PLpro), 3C-like protease (3CLpro), and spike protein. Yu et al. (2020) Computational screening of antagonist against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. International Journal of Antimicrobial Agents, p.106012.	remdesivir	chloroquine	n3	luteolin	p85	nag	ribavarin
8 molecules against SARS-CoV-2 ACE2 receptor from Abdelli et al. via docking	Docking analysis was used to identify 8 molecules against the SARS-CoV-2 ACE2 receptor. From Table 1 of Abdelli et al. (2020) In silico study the inhibition of Angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from western Algeria. Journal of Biomolecular Structure and Dynamics, (just-accepted), pp.1-17.	chloroquine	captopril	thymol	gamma-terpinene	isothymol	limonene	beta-d-mannose (co-crystallized ligand)	p-cymene
12 natural molecules against SARS-CoV-2 TMPRSS2 from Rahman et al. via docking	Docking analysis was used to identify 12 natural molecules against SARS-CoV-2 TMPRSS2. From Figure 3 of Rahman et al. (2020) Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2). Molecules, 25(10), p.2271.	excavatolide m	5'-methoxyhydnocarpin d	microcarpin	curtisian l	schisphenin a	durumolide k	(-)-epicatechin 3-o-(3'-o-methyl)gallate	isogemichalcone b	cytidine-5'-diphosphocholine	npc163169	geniposide	dictyosphaeric acid a
2 compounds from Traditional Mongolian Medicine against SARS-CoV-2 spike protein from Yu et al. via docking	Docking analysis was used to identify 2 compounds from Traditional Mongolian Medicine against the SARS-CoV-2 spike protein (S-protein). Yu et al. (2020) Exploring the Active Compounds of Traditional Mongolian Medicine in Intervention of Novel Coronavirus (COVID-19) Based on Molecular Docking Method. Journal of Functional Foods, p.104016.	phillyrin	chlorogenic acid
2 drugs against SARS-CoV-2 helicase protein from Borgio et al. via docking	Docking analysis was used to identify 2 approved drugs for repurposing against SARS-CoV-2 helicase protein. Borgio et al. (2020) State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2. Archives of Medical Science: AMS, 16(3), p.508.	atazanavir	vapreotide
Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition	Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition	celecoxib	carprofen
14 potential drugs to treat SARS-CoV-2 infection from a phosphoproteomics study	SARS-CoV-2 infection of Vero E6 cells, treatment of COVID-19 through regulation of kinase pathways and networks	silmitasertib	gilteritinib	valproic acid	scriptaid	geldanamycin	bortezomib	apilimod	trichostatin a	ralimetinib	dinaciclib	arry-797	sb203580	bencentinib	mapk13-in-1
Transcriptome-based drug repositioning for coronavirus disease 2019 (COVID-19)	Using bronchoalveolar lavage fluid transcriptome data of COVID-19 patients, we implemented a coexpression drug repositioning analysis, cogena, and identified two antiviral drugs (saquinavir and ribavirin) and several other candidate drugs (such as dinoprost, dipivefrine, dexamethasone and (-)-isoprenaline).	saquinavir	ribavirin	leflunomide	clozapine	raloxifene	dexamethasone	(-)-isoprenaline	dicycloverine	ozagrel	isocorydine	lisuride	phenylpropanolamine	dipivefrine	pergolide	methylergometrine	nabumetone	dinoprost	epirizole	aconitine